Refractory B-Cell Lymphoma Clinical Trials

3 recruiting

Frequently Asked Questions

Common questions about Refractory B-Cell Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1Phase 2

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

B-cell Lymphoma RecurrentRefractory B-Cell Lymphoma
Instituto de Investigación Biomédica de Salamanca27 enrolled8 locationsNCT06378190
Recruiting
Phase 1Phase 2

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

Relapsed and/or Refractory B-cell Lymphoma
Kite, A Gilead Company247 enrolled14 locationsNCT04989803
Recruiting
Phase 2

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Grade 3b Follicular Lymphoma+19 more
David Bond, MD37 enrolled1 locationNCT05821088
Recruiting
Phase 1Phase 2

Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma

Relapsed/Refractory B-cell Lymphoma
Shenzhen University General Hospital20 enrolled1 locationNCT07097207
Recruiting

Study of CAR-T Therapy in Older Patients

High-grade B-cell LymphomaMultiple MyelomaLymphoma+3 more
Memorial Sloan Kettering Cancer Center154 enrolled1 locationNCT04300998
Recruiting
Phase 2

Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma

Follicular LymphomaRelapsed Non Hodgkin LymphomaRefractory B-Cell Lymphoma
The First Affiliated Hospital of Xiamen University33 enrolled1 locationNCT06158386
Recruiting
Phase 4

Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma

Relapsed or Refractory B-cell Lymphoma
Ruijin Hospital8 enrolled1 locationNCT05806580
Recruiting
Phase 1

L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma

Relapsed/Refractory B-cell Lymphomas
Henan Cancer Hospital22 enrolled1 locationNCT06478381
Recruiting
Phase 1

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

Advanced Solid TumorsRelapsed/Refractory B-cell Lymphoma
InSilico Medicine Hong Kong Limited60 enrolled2 locationsNCT06445517